Trial Profile
A phase II, open label, non-randomized study of second or third line treatment with the combination of sorafenib and everolimus in patients affected by relapsed and non-resectable high-grade osteosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Everolimus
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms SERIO
- 03 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2014 Planned end date changed from 1 Sep 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 10 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.